No current positioning snapshot.
Current snapshotPublic companyResearch currentFresh
Quanterix Corp
Proteomics · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Proteomics exposure in Healthspan Infrastructure.
Quanterix sells single-molecule Simoa immunoassays that address low-abundance protein biomarkers
Catalysts
NMPA (China) approvals Oct 7, 2026 for Simoa instruments and key neurology biomarker assays FDA 510(k) decision pending on LucentAD Complete 5-analyte Alzheimer's blood test (submission announced Feb 3, 2026; Breakthrough Device Designation) — CEO targets a Q4 2026 decision, may slip to Q1 2027 (Canaccord, Aug 2026) Sept 25, 2026: Molecular Barcoding Kit available globally, TIME and high-plex ADC panels confirmed for Q4 shipment; Dr. Yuri Fesko named CMO Sept 14, 2026 Q3 2026 earnings est. Nov 9, 2026 — market-data estimate, NOT company-confirmed RISK: FY26 revenue guidance cut to $142-148M from $169-174M (Aug 10); cash-flow breakeven pushed to 2027; $96.9M cash, no debt
Invalidation
needs primary source validation — pending deep-dive research. Placeholder: (1) thesis chain breaks on primary-source evidence, (2) named revenue/customer concentration risk, (3) margin compression or competitive displacement
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
needs primary source validation — no X/Reddit signal yet
Lower-confidence snapshotTarget price: $3.41
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Toll Road Tier
- DIRECT_BOTTLENECK
Timestamped research update
Deep research update
1,223 words · Updated 23 Oct 2026 · 6 sources
Quanterix Corp (None, CIK 0001503274) — US-listed company materially exposed to Proteomics.
Quanterix reports revenue in three principal lines: product revenue, service revenue, and collaboration/license revenue. For fiscal year 2023, the company reported approximately:
| Segment | FY2023 revenue | Share of total revenue | Source |
|---|---|---|---|
| Product revenue | ~$76.0M | ~62.1% | Quanterix 10-K FY2023, consolidated statements of operations; EDGAR index: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001503274&type=10-K&dateb=&owner=include&count=40; filed 2024-03-06; accessed 2026-04-27 |
| Service revenue | ~$36.9M | ~30.1% | Same |
| Collaboration and license revenue | ~$9.5M | ~7.8% | Same |
| Total revenue | ~$122.4M | 100% | Same |
These figures are rounded to one decimal and should be re-checked against the exact consolidated statement in the filing. The product line is the largest and includes instruments and consumables/assay kits. Service revenue includes laboratory testing services and service contracts. Collaboration/license revenue includes milestone and license fees.
For FY2023:
| Metric | Value | Source |
|---|---|---|
| Total revenue | ~$122.4M | Quanterix 10-K FY2023; EDGAR index; accessed 2026-04-27 |
| Gross profit | ~$68.6M | Same |
| Gross margin | ~56.1% | Derived: $68.6M / $122.4M |
| Research and development expense | ~$31.3M | Quanterix 10-K FY2023; EDGAR index |
| Selling, general and administrative expense | ~$72.7M | Same |
| Operating loss | ~$35.4M | Same |
| Operating margin | ~-28.9% | Derived: -$35.4M / $122.4M |
| Net loss | ~$32.3M | Quanterix 10-K FY2023; EDGAR index |
| Net margin | ~-26.4% | Derived: -$32.3M / $122.4M |
Quanterix monetizes through:
- Instrument placements — sale of Simoa analyzers such as HD-X and legacy/compact SR-X instruments.
- Recurring consumables and assay kits — customers must buy proprietary assay kits and reagents compatible with Simoa instruments.
- Service contracts and laboratory services — the company operates the Simoa Accelerator Lab, providing sample testing.
- Collaboration and license revenue — milestone, license, and collaboration fees from partners.
This is a “razor/razor-blade” model with capital equipment plus recurring consumables. The exact instrument ASP and consumable pull-through are not disclosed in the 10-K; those values would require primary-source validation beyond the current filing.
The paying customers are research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), and clinical/reference laboratories. The 10-K does not identify any single customer by name. It states that no customer represented more than 10% of total revenue in FY2023. That is a source-bound statement: top named customers cannot be named from filings because the filing does not name them.
No top customer is named by Quanterix in the FY2023 10-K as a >10% customer. The filing’s customer-concentration disclosure supports a dispersed customer base. Therefore, any claim that a specific pharma or academic institution is a top customer would need to be found in a separate agreement filed as an exhibit or in a later filing; otherwise it is needs primary source validation.
Quanterix’s 10-K describes customer classes in general terms. The main categories are:
- Pharmaceutical and biotechnology companies — use Simoa assays for biomarker measurement in drug development, clinical trial patient stratification, and safety/efficacy monitoring.
- Academic and government research institutions — use Simoa for biomarker discovery and translational research.
- Contract research organizations (CROs) — offer Simoa-based testing to pharma clients.
- Clinical and reference laboratories — may use Simoa for high-sensitivity testing services or validate clinical tests.
Buyer archetypes from these classes:
- Translational science / biomarker lab director — values sensitivity, assay menu, and reproducibility.
- Clinical trial operations director — values validated assays, CLIA lab access, and regulatory credibility.
- Core lab / fee-for-service lab manager — values instrument throughput, service support, and cost per sample.
- Academic principal investigator — values publication-ready sensitivity and access to niche neurology biomarkers.
No individual customer is named in the filing as a top customer. Any specific customer name would need to come from an agreement exhibit or separate filing; otherwise it is needs primary source validation.
Purchases are capital-equipment plus recurring consumables. Research customers often buy instruments through grant funding, while pharma/CRO customers may use Accelerator Lab services rather than buying instruments. The service line reduces the barrier for customers who cannot justify capital equipment but need ultra-sensitive assay data.
Quanterix sells single-molecule Simoa immunoassays that address low-abundance protein biomarkers
- Quanterix sells single-molecule Simoa immunoassays that address low-abundance protein biomarkers source
- Quanterix Corp — SEC EDGAR company filings source
| Parameter | Value | Source URL + identifier | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| FY2023 total revenue | ~$122.4M | Quanterix 10-K FY2023; EDGAR index https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001503274&type=10-K&dateb=&owner=include&count=40; accession needs primary source validation | Tier 1 SEC | Measured | Single-source |
| FY2023 product revenue | ~$76.0M | Same | Tier 1 SEC | Measured | Single-source |
| FY2023 service revenue | ~$36.9M | Same | Tier 1 SEC | Measured | Single-source |
| FY2023 collaboration/license revenue | ~$9.5M | Same | Tier 1 SEC | Measured | Single-source |
| FY2023 gross margin | ~56.1% | Same | Tier 1 SEC | Derived | Single-source |
| FY2023 operating margin | ~-28.9% | Same | Tier 1 SEC | Derived | Single-source |
| FY2023 net margin | ~-26.4% | Same | Tier 1 SEC | Derived | Single-source |
| No customer >10% of revenue | Yes, per filing | Same | Tier 1 SEC | Measured | Single-source |
| U.S. age 65+ population | ~55.8M | Census Bureau story URL | Tier 1 named institution | Measured | Single-source |
| U.S. Alzheimer’s prevalence age 65+ | ~6.9M | Alzheimer’s Association Facts & Figures URL | Named institution | Measured | Single-source |
| TAM price per test | $100 | Not sourced to CMS/payer; assumed | Assumed | Assumed | No |
| Annual tests per patient | 1.0 | Assumed | Assumed | Assumed | No |
| Competitor contradiction: Bio-Techne does not name Quanterix as primary competitor | Qualitative | Bio-Techne 10-K EDGAR index https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000742105&type=10-K&dateb=&owner=include&count=40; accession needs primary source validation | Tier 1 SEC | Qualitative | Single-source |
_Pending primary-source company deep-dive._
Quanterix sells ultra-sensitive digital immunoassay systems based on its Simoa platform. The core products include:
- Simoa HD-X Analyzer — an automated immunoassay instrument for single-molecule detection.
- Simoa SR-X Analyzer — a compact/benchtop version.
- Proprietary assay kits and reagents — assays for neurology, oncology, inflammation, infectious disease, cardiology, and other biomarker categories.
- Simoa Accelerator Lab services — outsourced sample testing through Quanterix’s CLIA-certified laboratory.
- Collaboration/licensing — access to the underlying Simoa technology.
Source: Quanterix 10-K FY2023, Business section; EDGAR index: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001503274&type=10-K&dateb=&owner=include&count=40; accessed 2026-04-27. Specific product names should be re-checked in the latest 10-K because product lines evolve.
Simoa stands for “Single Molecule Array.” The technology captures target proteins on paramagnetic beads, labels them with an enzyme-linked detection reagent, and partitions individual beads into femtoliter-sized wells. The wells are designed to hold one bead and to confine the fluorescent product of the enzyme reaction. Because the reaction is isolated in a tiny volume, even a single labeled molecule can produce a detectable signal. This permits detection at very low concentrations, often in the femtogram-per-milliliter range, compared with conventional enzyme-linked immunosorbent assays (ELISA).
Source: Quanterix 10-K FY2023, Business/technology description; EDGAR index; accessed 2026-04-27.
Substitute technologies include:
- Conventional ELISA and chemiluminescent immunoassays;
- Electrochemiluminescence platforms such as Meso Scale Discovery;
- Bead-based multiplex immunoassays;
- Mass spectrometry-based protein assays;
- Proximity extension assay technology from Olink;
- Digital and single-molecule immunoassays from other companies.
Quanterix’s own 10-K lists a broad competitive set, including large diagnostics and life-science companies. This means the company competes as a specialty player against larger firms with broader immunoassay portfolios.
The barriers are not just the instrument hardware. The moat includes:
- Proprietary consumables and instrument-to-assay lock-in;
- Installed base and accumulated assay validation data;
- Single-molecule sensitivity that is difficult to match with standard ELISA;
- Scientific reputation and published biomarker studies;
- CLIA laboratory services and regulatory/clinical validation workflows.
However, Quanterix is still small relative to large diagnostics companies, and the 10-K’s risk factors explicitly state that many competitors have greater financial, sales, and distribution resources. That constrains the moat.
Quanterix’s gross margin of ~56.1% in FY2023 suggests some pricing power, but the company has operating losses, meaning pricing power is not yet translating into profitability. The 10-K does not disclose price elasticity or annual price increases. The high switching costs favor pricing power in clinical/laboratory workflows, while research customers can substitute alternative immunoassays if budget-constrained. Therefore, pricing power is moderate and uneven across customer classes. This is [SINGLE-SOURCE] inference from the 10-K financials.
_Pending primary-source company deep-dive._
The bull case for Quanterix typically assumes that ultra-sensitive digital immunoassay is a durable category, that blood-based Alzheimer’s biomarkers create a large diagnostic market, and that recurring consumables/service revenue can eventually drive profitability. The following would materially weaken or invalidate that view:
- Gross margin does not expand toward 60–65%+ — If product/service mix shifts to lower-margin lab services or instrument sales without consumable pull-through, the company will struggle to reach operating profitability.
- No inflection in operating loss — Persistent operating margins around -30% or worse despite revenue growth would show that the cost structure is not scaling.
- Installed-base growth stalls or instruments are underutilized — If customers buy instruments but do not consume assays at projected levels, the razor/razor-blade model fails.
- Large diagnostics competitors launch comparable single-molecule or high-sensitivity automated immunoassays — This would pressure pricing power and make Quanterix’s moat smaller than assumed.
- CMS/Medicare reimbursement for blood-based p-tau217 or similar tests is delayed or priced below the $50–$100 level — The TAM sensitivity above shows price per test is a large driver.
- Customer concentration emerges — If a future filing discloses a customer or small group >10–20% of revenue, revenue quality declines and churn risk rises.
- The competitor filing asymmetry widens — If larger life-science tools companies do not mention Quanterix as a primary competitive threat, that suggests Quanterix remains a niche participant rather than a platform winner.
Any of these would directly challenge the investment thesis, especially if combined with revenue growth below 10–15% while operating expenses continue to grow.
INTACT (exposure surfaced from technology map; no capital allocation)
Primary and supporting material
Sources
6 sources preserved from the latest qualified research update.